Metastatic Melanoma Patient-derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition

PURPOSE: Over 60 % of melanoma patients respond to immune checkpoint inhibitor (ICI) therapy, but many subsequently progress on these therapies. Second-line targeted therapy is based on BRAF mutation status, but no available agents are available for NRAS, NF1, CDKN2A, PTEN, and TP53 mutations. Over...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cancer Res
Päätekijät: Shattuck-Brandt, Rebecca L., Chen, Sheau-Chiann, Murray, Emily, Johnson, C. Andrew, Crandall, Holly, O’Neal, Jamye F., Al-rohil, Rami Nayef, Nebhan, Caroline A., Bharti, Vijaya, Dahlman, Kimberly B., Ayers, Gregory D., Kelley, Mark, Kauffmann, Rondi M., Hooks, Mary, Grau, Ana, Johnson, Douglas B., Vilgelm, Anna E., Richmond, Ann
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7367743/
https://ncbi.nlm.nih.gov/pubmed/32234759
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1895
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia